Skip to Content

Protalix BioTherapeutics Inc PLX

Morningstar Rating
$1.25 +0.03 (2.46%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

PLX is trading at a 50% discount.
Price
$1.22
Fair Value
$7.36
Uncertainty
Extreme
1-Star Price
$1.60
5-Star Price
$5.43
Economic Moat
Mklm
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PLX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.22
Day Range
$1.221.28
52-Week Range
$1.213.55
Bid/Ask
$1.23 / $1.25
Market Cap
$91.32 Mil
Volume/Avg
321 / 339,855

Key Statistics

Price/Earnings (Normalized)
59.93
Price/Sales
1.57
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
208

Comparables

Valuation

Metric
PLX
MRNA
SRPT
Price/Earnings (Normalized)
59.9341.17
Price/Book Value
2.723.0514.20
Price/Sales
1.576.259.68
Price/Cash Flow
11.17
Price/Earnings
PLX
MRNA
SRPT

Financial Strength

Metric
PLX
MRNA
SRPT
Quick Ratio
1.093.213.23
Current Ratio
1.543.423.95
Interest Coverage
3.29−113.82−26.54
Quick Ratio
PLX
MRNA
SRPT

Profitability

Metric
PLX
MRNA
SRPT
Return on Assets (Normalized)
15.24%−20.12%−1.58%
Return on Equity (Normalized)
57.64%−26.85%−7.14%
Return on Invested Capital (Normalized)
27.39%−26.68%−4.76%
Return on Assets
PLX
MRNA
SRPT
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRWtynwlfbyBhjc$571.0 Bil
VRTX
Vertex Pharmaceuticals IncNqcscbzmJjvpt$107.8 Bil
REGN
Regeneron Pharmaceuticals IncJhzlnwnyFjzlhf$106.1 Bil
MRNA
Moderna IncPcmlqvxVkck$42.3 Bil
ARGX
argenx SE ADRDbqgjhszGtzd$23.7 Bil
BNTX
BioNTech SE ADRGkkgwnwwXffh$22.1 Bil
ALNY
Alnylam Pharmaceuticals IncXfqhyhlfzBdtwvy$19.4 Bil
BMRN
Biomarin Pharmaceutical IncYlspvnsQwsnhvk$16.7 Bil
RPRX
Royalty Pharma PLC Class ADnwngwgmzrBctrzl$13.6 Bil
INCY
Incyte CorpZrfmfyyTddlxh$12.8 Bil

Sponsor Center